Changing lives with plant-based medicines

We are a bio-pharma company utilising the medical value of phytocannabinoids to provide relief to people suffering across the globe.

Creating the future of medicine from natural ingredients

Our goal is to provide cost effective, standardized, affordable medicines. We are leaders in the conceptualization, formulation and creation of products that are consistent, regulation compliant, plant-derived medicines. We want to perfect the pathway from nature to medicine through a robust clinical pipeline.

Plant-based medicines to treat

Epilepsy

Epilepsy

CannEpil® is a product with CBD-THC content that has been shown to be safe and efficacious in real world settings when used to control seizures that could not be effectively managed by standard medical treatments.

Dementia

Dementia

CogniCann® is currently in clinical development for the management of BPSD (Behavioural and Psychological Symptoms in Dementia) based on real world data which supports the potential for this implementation.

COVID-19

COVID-19

CimetrA™ have demonstrated its effectiveness during Stage II clinical trials and serve to modulate inflammatory / immune markers associated with the COVID-19 virus.

Cancer

Cancer

Clinical experience supports the use of various cannabinoid-based formulations for the amelioration of a range of diseases and the treatment of related symptoms. These include various types of pain, pruritus (itching), sleep disorders, poor appetite, anxiety and more.

Crohn's Disease

Crohn's Disease

Cannabinoids, such as those made available in MGC products have been used both historically and in recent times, with particular success in Crohn’s disease for the management of symptoms such as pain, loss of appetite, and diarrhoea.

Cerebral Palsy

Cerebral Palsy

Clinical experience corroborates the evidence-based use of cannabinoids for the management of seizures and spasticity, both of which have a substantial impact on the lives of those affected by cerebral palsy as well as their caretakers and families.

CannEpil® is a product with CBD-THC content that has been shown to be safe and efficacious in real world settings when used to control seizures that could not be effectively managed by standard medical treatments.

CogniCann® is currently in clinical development for the management of BPSD (Behavioural and Psychological Symptoms in Dementia) based on real world data which supports the potential for this implementation.

CimetrA™ have demonstrated its effectiveness during Stage II clinical trials and serve to modulate inflammatory / immune markers associated with the COVID-19 virus.

Clinical experience supports the use of various cannabinoid-based formulations for the amelioration of a range of diseases and the treatment of related symptoms. These include various types of pain, pruritus (itching), sleep disorders, poor appetite, anxiety and more.

Cannabinoids, such as those made available in MGC products have been used both historically and in recent times, with particular success in Crohn’s disease for the management of symptoms such as pain, loss of appetite, and diarrhoea.

Clinical experience corroborates the evidence-based use of cannabinoids for the management of seizures and spasticity, both of which have a substantial impact on the lives of those affected by cerebral palsy as well as their caretakers and families.

We are just scratching the surface of where plant-based treatments, intersected with modern science, will bring us back to balanced global health

Dr. Jonathan Grunfeld

VP Medical Innovation

Our Partners and Collaborators

We partner with leading institutions, companies and groups worldwide, to support expanding the agenda of plant-based medicines supporting unmet needs.

Research, Clinical and Academia

Education & Patient Access Partners

Distribution, Logistics, Manufacturing

Leading the global shift towards plant-based, naturally harmonious medicines, improving lives and public health.

Rob Clements

Chief Commercial Officer

After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.

He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.

From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.

An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.

From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.